MarketVIEW: Respiratory Syncytial virus vaccines

  • May 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd
  • -
  • 60 pages

Respiratory syncytial virus (RSV) is a leading cause of infant/childhood lower respiratory tract infection and hospitalization. Elderly adults and those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. RSV is estimated to be responsible for ~9,000 deaths per year (US).

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in "at risk" groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is AstraZeneca/Medimmune's MEDI-534 and MEDI-559. US biotech Novavax have also completed a Phase I trial with VLP recombinant RSV-F fusion protein. 

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets to 2030. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups. Differing RSV vaccine profiles (infant + elderly) and related issues such as differential pricing are also discussed with regard to LO/BASE/HI market uptake scenarios. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Table Of Contents

Executive summary
Commercial model - key outputs
Total predicted demand (doses 000s), all scenarios
Total global available market ($000s), all scenarios
Total global available market ($000s), infant
Total global available market ($000s), adult “at risk”
Total global available market ($000s), adult “universal”
The role of a RSV vaccine
Vaccine target populations: overview
Vaccine target populations: scenario definitions
RSV vaccine: infant target product profile
RSV vaccine: adult target product profile
Markets included in the model
Commercial model assumptions: infant scenario
Commercial model assumptions: adult scenarios
Model forecast comparisons: March 2010 v current model (May 2012)
Pricing methodology: infant and adults
Competitor landscape overview
MedImmune: MEDI-534 and MEDI-559 vaccines
Novavax: VLP RSV-F vaccine
Novavax: Phase I data
Preclinical vaccines
Vaccine pipeline summary
Estimated launch dates
Opportunities for new treatments
Review of latest epidemiology
Epidemiology: infants
Epidemiology: adults
Epidemiology: hospitalizations
Methodology: target populations
Methodology: coverage
Model forecast comparisons: Novavax/LEK analysis
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents - Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME - HIGH
VALUE SUMMARY - universal
VALUE SUMMARY - “at risk”
VALUE SUMMARY - infants
VOLUME SUMMARY - universal
VOLUME SUMMARY - “at risk”
VOLUME SUMMARY - infants
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Brazil
India
China
Mexico
Country total populations - forecast to 2030 (Births, >18 yrs, >65 yrs)
Source material
US RSV
Japan RSV
US Pneumonia
Asthma/COPD epidemiology
CHF epidemiology
Cancer EPI
Pricing (infant)
Coverage (COPD and HF)
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...

DNA Vaccines: Technologies and Global Markets

DNA Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • July 2014
  • by BCC Research

This BCC Research study determines the specific applications and global market demand for DNA vaccine products over a five-year period from 2014 to 2019. High growth and market potential segments of the ...

Detailed I/E report of Carbendazim export analysis

Detailed I/E report of Carbendazim export analysis

  • $ 5 400
  • Industry report
  • July 2014
  • by CCM International Limited

Carbendazim export analysis will help clients indentify export situation of technical and formulations with exclusive research methods, to offer not only the target products' export volume, price, time, ...

Marketview: Rotavirus Vaccines

June 2014 $ 4 495

9 Companies

Company Profiles

Wyeth Ltd.

India

GlaxoSmithKline PLC

United Kingdom

AstraZeneca PLC

United Kingdom

Sopharma AD

Bulgaria

Alimera Sciences Inc.

United States

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

Amgen Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.